Downloads: 1
| # | Blank 1 | Frequency | Blank 2 | Frequency | Blank 3 | Frequency | |
|---|---|---|---|---|---|---|---|
| 1 | 4 | history of hypersensitivity to durvalumab or | 19 | 36 | 31 | ||
| 2 | 6 | history of hypersensitivity to durvalumab tremelimumab or | 4 | component / | 1 | . | 5 |
| 3 | 2 | known hypersensitivity to | 2 | study related agent | 1 | of prs 343 . | 1 |
| 4 | 5 | history of hypersensitivity to tremelimumab or | 2 | of the investigational agents under test or any | 1 | s | 1 |
| 5 | 13 | history of hypersensitivity to durvalumab or tremelimumab or | 2 | component of the investigational product pvx 410 durvalumab or any | 1 | of these products | 1 |
| 6 | 25 | history of hypersensitivity to medi4736 or | 2 | NA | in nc 6300 . | 1 | |
| 7 | 1 | history of infusion reactions to | 1 | NA | NA | ||
| 8 | 3 | history of hypersensitivity to tremelimumab durvalumab or | 1 | NA | NA | ||
| 9 | 10 | known hypersensitivity to st2210 dota biotin or | 1 | NA | NA | ||
| 10 | 16 | or | 1 | NA | NA | ||
| 11 | 18 | hypersensitivity to | 1 | NA | NA | ||
| 12 | 19 | history of hypersensitivity to durvalumab medi4736 tremelimumab or | 1 | NA | NA | ||
| 13 | 20 | 1 | NA | NA | |||
| 14 | 29 | history of hypersensitivity to durvalumab guadecitabine sgi 110 or | 1 | NA | NA | ||
| 15 | 39 | have known hypersensitivity to anthracycline compounds or | 1 | NA | NA |